-The Hindu     The much-awaited Drug (Prices Control) Order 2013 has disappointed millions of patients, as it lacks a fair formula to fix the price ceiling and leaves important drug classes out of regulation. The result: High out-of-pocket spending on medicines will continue As far as intentions go, the Drug (Prices Control) Order 2013 is aimed at making critical drugs affordable and available to the public, while preserving a rationale for manufacture by...

-The Hindu There has been no public debate on the level of watch citizens can be put through, and on what the red lines should be while using intrusive mechanisms The tussle between government agencies' need for a better, faster and real-time interception, surveillance and monitoring mechanism through the Central Monitoring System (CMS), on the one hand, and demands by privacy, civil rights and free speech activists, for ensuring higher privacy for...

-The Business Standard Madhya Pradesh Chief Minister Shivraj Singh Chouhan on the launch of the second phase of the Mukhya Mantri Annapurna Yojana, ahead of the Centre's proposed food security legislation. Edited excerpts of an interview with Sanjay Jog: * What are the key features of the second phase of the Mukhya Mantri Annapurna Yojana (MAY), launched from this month? This will benefit 35 million people, including 5.5 mn below the poverty line...

-Frontline   But in Modi's Gujarat the difference between development and darkness is all too visible to those who care to see. NARENDRA MODI may have won three consecutive elections and ruled Gujarat for more than a decade after he was posted there almost as a night watchman, to borrow a cricketing expression. He may have mobilised a massive fan following that is shouting to catapult him into the Prime Minister's post,...

-The Business Standard The Novartis verdict by the Supreme Court emphasised the importance of flexibilities in drug patent laws, in contrast to Western countries which are seeking TRIPS-plus hardening through free-trade agreements As curtains on the six-year-long legal tussle with Swiss drug giant Novartis AG finally came down earlier this month, the Indian government did not waste a second in hailing the Indian patent law which it said was in "full...